HC Wainwright Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX)

HC Wainwright assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report published on Friday, MarketBeat reports. The brokerage issued a buy rating and a $42.00 price target on the stock.

Several other equities analysts have also recently issued reports on BCAX. Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating for the company. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Morgan Stanley initiated coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Stock Up 8.0 %

Bicara Therapeutics stock opened at $21.10 on Friday. Bicara Therapeutics has a 52 week low of $17.41 and a 52 week high of $28.09. The stock’s fifty day simple moving average is $21.73.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, research analysts forecast that Bicara Therapeutics will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 74.20 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. RA Capital Management L.P. acquired a new stake in Bicara Therapeutics in the third quarter worth $177,169,000. FMR LLC acquired a new stake in Bicara Therapeutics in the third quarter worth $57,913,000. Braidwell LP acquired a new stake in Bicara Therapeutics in the third quarter worth $42,219,000. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics in the third quarter worth $30,329,000. Finally, Baker BROS. Advisors LP acquired a new stake in Bicara Therapeutics in the third quarter worth $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.